Targetable Molecular Profiles in Salivary Duct Carcinoma: A Review and Case Study of Molecular Diagnostic and Therapeutic Implications.

IF 1 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY

Diagnostic Cytopathology Pub Date : 2025-07-04 DOI:10.1002/dc.25501

Gloria Hopkins Sura

{"title":"Targetable Molecular Profiles in Salivary Duct Carcinoma: A Review and Case Study of Molecular Diagnostic and Therapeutic Implications.","authors":"Gloria Hopkins Sura","doi":"10.1002/dc.25501","DOIUrl":null,"url":null,"abstract":"<p><p>Salivary duct carcinoma is a rare, high-grade malignancy of the salivary glands, most commonly arising in the parotid. This review highlights recent advancements in the cytologic, immunophenotypic, and molecular characterization of salivary duct carcinoma, emphasizing the central role of biomarkers such as androgen receptor (AR) overexpression and ERBB2 (HER2) amplification in diagnosis, prognosis, and therapeutic decision-making. These principles are illustrated through the case of a 55-year-old male with AR-positive, HER2-amplified salivary duct carcinoma of the right parotid gland with nodal and osseous metastases. Diagnosis was established via fine-needle aspiration (FNA) cytology, immunocytochemistry, and molecular profiling. The patient underwent androgen deprivation therapy followed by treatment with a HER2 targeted antibody-drug conjugate, achieving disease stability. This case exemplifies how molecular diagnostics inform personalized treatment strategies in salivary duct carcinoma and underscores the need for standardized testing protocols and greater awareness of precision oncology approaches in salivary gland malignancies.</p>","PeriodicalId":11349,"journal":{"name":"Diagnostic Cytopathology","volume":" ","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diagnostic Cytopathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/dc.25501","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Salivary duct carcinoma is a rare, high-grade malignancy of the salivary glands, most commonly arising in the parotid. This review highlights recent advancements in the cytologic, immunophenotypic, and molecular characterization of salivary duct carcinoma, emphasizing the central role of biomarkers such as androgen receptor (AR) overexpression and ERBB2 (HER2) amplification in diagnosis, prognosis, and therapeutic decision-making. These principles are illustrated through the case of a 55-year-old male with AR-positive, HER2-amplified salivary duct carcinoma of the right parotid gland with nodal and osseous metastases. Diagnosis was established via fine-needle aspiration (FNA) cytology, immunocytochemistry, and molecular profiling. The patient underwent androgen deprivation therapy followed by treatment with a HER2 targeted antibody-drug conjugate, achieving disease stability. This case exemplifies how molecular diagnostics inform personalized treatment strategies in salivary duct carcinoma and underscores the need for standardized testing protocols and greater awareness of precision oncology approaches in salivary gland malignancies.

查看原文本刊更多论文

涎腺导管癌的靶向分子特征：分子诊断和治疗意义的回顾和案例研究。

唾液腺管癌是一种罕见的、高度恶性的唾液腺肿瘤，最常见于腮腺。本文综述了涎腺导管癌细胞学、免疫表型和分子特征的最新进展，强调了雄激素受体（AR）过表达和ERBB2 （HER2）扩增等生物标志物在诊断、预后和治疗决策中的核心作用。这些原则通过一个55岁男性右腮腺ar阳性，her2扩增的涎腺导管癌伴淋巴结和骨转移的病例来说明。诊断通过细针穿刺（FNA）细胞学，免疫细胞化学和分子谱建立。患者接受雄激素剥夺治疗，随后接受HER2靶向抗体-药物偶联物治疗，实现疾病稳定。该病例说明了分子诊断如何为唾液腺导管癌的个性化治疗策略提供信息，并强调了标准化检测方案的必要性和对唾液腺恶性肿瘤精确肿瘤学方法的更高认识。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diagnostic Cytopathology 医学-病理学

CiteScore

2.60

自引率

7.70%

发文量

163

审稿时长

3-6 weeks

期刊介绍： Diagnostic Cytopathology is intended to provide a forum for the exchange of information in the field of cytopathology, with special emphasis on the practical, clinical aspects of the discipline. The editors invite original scientific articles, as well as special review articles, feature articles, and letters to the editor, from laboratory professionals engaged in the practice of cytopathology. Manuscripts are accepted for publication on the basis of scientific merit, practical significance, and suitability for publication in a journal dedicated to this discipline. Original articles can be considered only with the understanding that they have never been published before and that they have not been submitted for simultaneous review to another publication.